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Saudi womenAbstract There are no earlier studies that reported the association of the 12Glu9 polymorphism in
the alpha-2B adrenoceptor (ADRA2B) gene with gestational diabetes mellitus (GDM). We examined
the potential association between the ADRA2B gene insertion/deletion (I/D) polymorphism in the
Saudi population with GDM. Pregnant women with GDM have been reported to exhibit the same
susceptibility as that observed in type 2 diabetes mellitus (T2DM). We have selected I/D polymor-
phism of the ADRA2B gene located in chromosome 2q11.1 that has been extensively related to
T2DM and cardiovascular diseases. This case–control study was conducted with 200 GDM and
300 non-GDM pregnant women. Genotyping of I/D polymorphism was performed by conventional
PCR method. Biochemical analyses were found to be signiﬁcantly different between GDM and non-
GDM subjects (p< 0.05). Genotype (ID + DD vs II, p = 0.0002) and allele (D vs I, p= 0.0002)
frequencies of the 12Glu9 polymorphism were found to be statistically signiﬁcant. However, a signif-
icant difference was found between allele and genotypes of I/D polymorphism of the ADRA2B gene
or the clinical characteristics of the subjects. Our results obtained in this study indicate the ADRA2B
gene in the Saudi women was associated with the development of GDM.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Gestational diabetes mellitus (GDM) remains one of the most
common clinical issues that obstetrician’s face (Hiraoka et al.,
2011). The clinical characteristics of pregnant women that are
associated with a high risk for GDM include obesity, increased
Body Mass Index (BMI), family history of type 2 diabetes




First hour 10.0 180
Second hour 8.6 155
Third hour 7.8 140
** mg/dL – milligram/deciliter.
* mmol/L – milli molar/liter.
Insertion and deletion polymorphism studies 129mellitus (T2DM)/GDM, advanced maternal age, and glycos-
uria (Chon et al., 2013). GDM is a common pregnancy compli-
cation and a strong predictor for T2DM (Hedderson et al.,
2013). Epidemiological studies have conﬁrmed that GDM is
associated with increased feto-maternal morbidity and long-
term complications in both the mothers and offspring. The
pathogenesis of GDM is largely unknown. Women with a his-
tory of GDM are at an increased risk of developing T2DM
later in their lives, and women with a family history of diabetes
may be predisposed to an increased risk of GDM (Wang et al.,
2012). GDM and T2DM share common pathophysiological
features, including b-cell dysfunction and insulin resistance.
The prevalence of GDM and T2DM continue to increase in
many racial/ethnic populations. In the Kingdom of Saudi
Arabia, the overall prevalence of GDM and T2DM is 22%
(Wahabi et al., 2013) and T2DM has 23.1% respectively
(Al-Daghri et al., 2012).
A common nonsynonymous variant (12Glu9) of the human
a2B-adrenergic gene (ADRA2B) encodes a receptor protein
leading to the insertion/deletion (I/D) of three consecutive glu-
tamate residues at amino acid positions 301–303, and it has
been associated with hypertension/T2DM (Vasudevan et al.,
2008) and acute coronary events (Heinonen et al., 2002;
Snapir et al., 2001). Vasudevan and coworkers (2008) found
that the ADAR2B I/D polymorphism was associated with
T2DM in Malaysian subjects. However, the exon 1 region of
the ADAR2B I/D polymorphism has not been reported in
GDM. Therefore, the goal of the present study was to deter-
mine whether the ADAR2B I/D polymorphism plays an
important role in Saudi pregnant women who develop GDM.
2. Materials and methods
2.1. Study design
In this case–control study, we selected 500 pregnant women
from the Department of Obstetrics and Gynecology, King
Khalid University Hospital (KKUH), King Saud University,
Riyadh, Saudi Arabia. The study included 200 GDM women
who developed diabetes during pregnancy and 300 non-
GDM women. We excluded 132 antenatal patients who were
prediagnosed with type 1 or type 2 diabetes. Non-GDM
women had normal glucose levels and demonstrated normal
glucose tolerance (NGT). Samples of 5 mL of venous blood
were collected from all pregnant women; 3 mL of each serum
sample was used for biochemical analysis to conﬁrm the dis-
ease, and 2 mL of each ethylenediaminetetraacetic acid
(EDTA) sample was used for molecular analysis. The study
protocol was approved by the Institutional Review Board at
the Faculty of Medicine, King Saud University, and all preg-
nant women who participated in the study provided written
informed consent. GDM and non-GDM samples were
obtained by senior physician at KKUH.
2.2. Glucose test
Pregnant women without a previous diagnosis of glucose intol-
erance were routinely screened for GDM by two methods
between 24 and 28 weeks of gestation. Initially, a 50 g glucose
challenge test (GCT) was used as a preliminary screen. The
GCT was considered positive if the plasma glucose valuessurpassed 7.8 mmol/L. Pregnant women with positive GCTs
were evaluated with the second method, i.e., a 100 g oral glu-
cose tolerance test (OGTT). Diagnosis of GDM was based
on criteria set by the American Diabetes Association (Swan
et al., 2007). After an overnight fast that followed for three
days of unrestricted diet, fasting plasma samples were drawn
after one, two, and three hours of glucose administration.
The glucose threshold values are shown in Table 1. A diagnosis
of GDM was made if two or more of the glucose values met or
exceeded the threshold value. NGT was diagnosed when all
plasma glucose values were below the threshold values. Based
on the above criteria, 200 subjects with GDM and 300 with
NGT were recruited into the study. The NGT patients were
considered as controls, or non-GDM, for this study.
2.3. Anthropometric measurement
Anthropometric measurements were obtained by trained per-
sonnel at the health care centers. Height and body weight were
measured to the nearest 0.5 cm and 0.1 kg, respectively. Body
Mass Index (BMI) was calculated as weight/height2 (kg/m2).
Subjects with BMI > 30 kg/m2 were categorized as obese.
Waist circumference was measured to the nearest 0.5 cm at
the level of the midpoints of the lowest rib, and the hip circum-
ference was measured to the nearest 0.5 cm at the maximum
extension of the buttocks.
2.4. Biochemical analysis
Fasting and postprandial blood and lipid proﬁle biochemical
parameters were assessed. High-density lipoprotein-cholesterol
(HDL-C), triglycerides (TG), total cholesterol (TC), and
plasma glucose were measured with an automated clinical
chemistry analyzer (Kit provided by KoneLab, Espoo,
Finland) using commercially available kits. Dyslipidemia (low
levels of HDL-C) was deﬁned as HDL-C levels <1.03 mmol/
L formen and<1.29 mmol/L for women (Almeida et al., 2011).
2.5. Genetic analysis
DNA was extracted from peripheral leukocytes using the stan-
dard AccuVis Bio DNA extraction kit (AccuVis Bio, UAE).
DNA samples were store at 80 C. The concentration of
genomic DNA was quantitatively determined by optical den-
sity measurements using a NanoDrop 2000 (Thermo Fisher
Scientiﬁc, MA, and USA). The purity was determined by
calculating the ratio of absorbance at 260 nm to absorbance
at 280 nm (A260/A280). Non-annealed DNA should have an
A260/A280 ratio of 1.7–1.9. For the 12Glu9 I > D polymor-
phism, the primers 50-AGGGTGTTTGTGGGGCATCT-30
130 M.M. Al-Hakeem et al.(sense) and 50-CAAGCTGAGGCCGGAGACACT-30 (anti-
sense) were used to amplify the ADAR2B gene D/D, I/D,
and I/I genotypes of the 112 bp fragment. Polymerase chain
reactions (PCRs) were performed in a thermal cycler (Applied
Biosystems, USA) with initial denaturation at 95 C for 5 min
followed by 35 cycles, with each cycle containing denaturation
at 95 C for 30 s, annealing at 57 C for 30 s, extension at 72 C
for 45 min, and ﬁnal extension at 72 C for 5 min. Ampliﬁca-
tion of the I/D polymorphism was performed in a total volume
of 20 lL reaction mixture composed of 2 lL (10 pmol) of each
primer, 6 lL of sterile water, and 10 lL of a 2·master mix that
included MgCl2, 10· Taq buffer, 10 unit of Taq DNA poly-
merase (Norgen Biotek corp, Canada), and 2 lL template
DNA. Primers were synthesized by Bioserve Biotechnologies
(Hyderabad, India). The ampliﬁed products were analyzed
by electrophoresis on a 12% polyacrylamide gel. The larger
allele of 12Glu9 contained 3 tandem, 9 bp repeats and it was
designated the insertion, and the smaller allele of 12Glu9 con-
tained no tandem repeats, being designated as the deletion.
The sizes of the PCR products were 112 bp and 103 bp for
the insertion and deletion alleles, respectively.
2.6. Statistical analysis
Clinical characteristics of all the subjects were expressed as the
mean ± SD. Alleles and genotype frequency differences
between GDM patients and non-GDM subjects were tested
using a chi-square test. Odds ratios (ORs) and 95% conﬁdence
intervals are calculated by binomial logistic regression for the
allele, genotype, and haplotype frequencies, and the chi-square
test was used to identify departures from the Hardy–Weinberg
equilibrium. Statistical analyses were performed with SPSS
version 19.0 software. A p-value of <0.05 was considered
statistically signiﬁcant.3. Results
3.1. Clinical characteristics
Clinical, biochemical, and anthropometric data are shown in
Table 2 for GDM and non-GDM subjects. The results show
that GDM subjects were signiﬁcantly older than controls,
but anthropometric measurements, including weight, height,
BMI and LDL-C were not signiﬁcantly different (p> 0.05).
The biochemical proﬁle, consisting of FBS, PPBG, GCT,
OGTT, TC, TG, and HDL-C was signiﬁcantly higher in
GDM patients compared with non-GDM subjects
(p< 0.05). Family histories of T2DM and GDM patients were
signiﬁcantly different between the groups (p< 0.05). Women
diagnosed with GDM were given dietary instructions by a
dietician as soon as possible after diagnosis. Ninety percent
of the GDM women were on diet, and 10% of them were using
insulin because they were unable to maintain normal blood
glucose levels by the diet.
3.2. Genotype and allele distribution
The genotype and allele distribution of 12Glu9 variants are
summarized in Table 3. Distribution of genotypes and allele
frequencies of the 12Glu9 polymorphism in GDM andnon-GDM women satisfy the Hardy–Weinberg equilibrium.
The genotype and allele frequencies for the 12Glu9 polymor-
phism were signiﬁcantly different between GDM and non-
GDM subjects. The results from this study show a high
prevalence of the DD genotype in GDM women (6.5%) com-
pared to non-GDM (2.3%). The frequency of the D allele was
15.2% in the GDM group and 7% in the non-GDM group.
Notably, a signiﬁcant association was observed between I/D
polymorphism and genotypes/allele frequencies, i.e., between
the ID + DD genotype and the D allele [OR-2.3 (1.48, 3.8),
p= 0.0002; OR-2.3 (1.57, 3.6), p= 0.0002].
3.3. Association of the ADRA2B gene variants with clinical and
biochemical parameters
The prevalence of different components of the ADRA2B gene
was analyzed based on the 12Glu9 polymorphisms and geno-
types. Results showed that the DD and ID genotypes were sig-
niﬁcantly associated only with TC (p = 0.03), whereas the II
genotype was found to have high values of weight, height,
BMI, FBS, PPBG, GCT, and HDL-C (p> 0.05). Family his-
tory of T2DM and GDM was found to be high among individ-
uals with the II genotype. More than 88% of the pregnant
women were on a diet, and 11.8% of the pregnant women were
on insulin (Table 4).
4. Discussion
There are many factors, such as obesity, family history of
T2DM, and other complications, that have been reported to
inﬂuence the pathogenesis of GDM, thought to be a multifac-
torial disease similar to essential hypertension, T2DM, and
chronic heart disease (CHD). The association of gene poly-
morphisms with GDM has been a major focus of recent
research. Our team genotyped a target SNP, rs4426564,
located at the 50-end of exon 1 of the ADRA2B gene. We stud-
ied I/D (12Glu9) polymorphism in Saudi women, grouped
according to those who do and do not develop GDM.
It is understood that the etiology of GDM is similar to
T2DM, where genetic and environmental factors affect disease
onset and progression during pregnancy. The hyperglycemia
associated with GDM is detected at one point in a women’s
life. If glucose levels are already in the diabetic range, GDM
could represent glucose intolerance that is limited to preg-
nancy, where it is chronic but stable, or the detected GDM
could indicate progression to diabetes (Buchanan and Xiang,
2005). The 12Glu9 or I/D polymorphism is linked to the auto-
nomic dysfunction and increased sympathetic nervous system
activity (Papanas et al., 2007). These characteristics have been
associated with adverse metabolic and vascular effects, includ-
ing reduced basal metabolic rate (Heinonen et al., 1999), obes-
ity (Siitonen et al., 2004), and earlier onset of diabetes
(Papazoglou et al., 2006), acute coronary ischemia (Snapir
et al., 2001), T2DM with neuropathy (Papanas et al., 2007),
sudden cardiac death (Laukkanen et al., 2009), spontaneous
abortions (Galazios et al., 2011), migraine (Ni et al., 2010),
glucose 6 phosphate dehydrogenase (Alharbi et al., 2013), sui-
cide (Fukutake et al., 2008), and hypertension with and with-
out T2DM (Vasudevan et al., 2008). Several studies of
subjects from different ethnic backgrounds have reported a
positive or negative association between the ADRA2B gene
Table 2 Clinical details.
S. No Aspects GDM cases (n= 200) Controls (n= 300) Statistical signiﬁcance
1 Age (Years) 32.43 ± 5.79 31.36 ± 6.02 p= 0.55
2 Weight (kg) 77.1 ± 13.34 74.85 ± 12.09 p= 0.12
3 Height (m2) 158.51 ± 5.92 157.81 ± 5.31 p= 0.08
4 BMI (kg/m2) 34.43 ± 4.68 33.36 ± 4.28 p= 0.16
5 Hypertension (%) 76 (38%) 14 (4.6%) p< 0.0001
6 Mean gestational age 30.27 ± 5.77 NA NA
7 FBS (mmol/L) 5.0 ± 0.93 4.5 ± 0.87 p< 0.0001
8 PPBG (mmol/L) 6.8 ± 2.0 4.9 ± 1.8 p= 0.0001
9 GCT (mmol/L) 9.5 ± 1.8 6.3 ± 1.5 p< 0.0001
10 OGTT (Fasting hour) 5.2 ± 1.18 4.5 ± 0.87 p< 0.0001
11 OGTT (1st hour) 10.7 ± 1.8 8.0 ± 1.7 p< 0.0001
12 OGTT (2nd hour) 9.2 ± 1.8 6.7 ± 1.6 p< 0.0001
13 OGTT (3rd hour) 5.6 ± 1.7 4.5 ± 1.3 p< 0.0001
14 TG (mmol/L) 2.3 ± 1.8 1.7 ± 0.98 p< 0.0001
15 TC (mmol/L) 5.7 ± 1.2 5.2 ± 1.0 p< 0.0001
16 HDL-C (mmol/L) 0.92 ± 0.38 0.64 ± 0.24 p< 0.0001
17 LDL-C (mmol/L) 3.7 ± 0.93 3.7 ± 1.0 p= 0.82
18 Family History of T2DM (n%) 120 (60%) 55 (18.3%) p< 0.0001
19 Family History of GDM (n%) 46 (23%) 13 (4.3%) p< 0.0001
20 Rx (Diet/Insulin) 180 (90%)/20 (10%) NA NA
NA= not applicable/not analyzed.
Table 3 Genotype distribution of 12Glu9 polymorphism in the individuals enrolled in the study.
Genotypes Non-GDM N (%) GDM N (%) Odds ratio (95% CI) p Value
N 300 200
II 265 (88.4) 152 (76) Reference –
ID 28 (9.3) 35 (17.5) 2.1 (1.27, 3.74) 0.003
DD 7 (2.3) 13 (6.5) 1.4 (0.52, 4.2) 0.45
ID + DD 35 (11.6) 48 (24) 2.3 (1.48, 3.8) 0.0002*
I 558 (93) 339 (84.8) Reference
D 42 (7) 61 (15.2) 2.3 (1.57, 3.6) 0.0002
* After continuity correction.
Table 4 Anthropometric and metabolic parameters according to genotype of 12Glu9 I> D polymorphism in GDM women.
S. No Aspects ID + DD (n= 48) II (n= 152) p Value
1 Age (Years) 33.58 ± 6.51 32.07 ± 5.46 p= 0.11
2 Weight (kg) 75.96 ± 14.99 77.46 ± 12.80 p= 0.15
3 Height (m2) 157.42 ± 6.30 158.86 ± 5.81 p= 0.46
4 BMI (kg/m2) 29.89 ± 4.89 30.48 ± 4.62 p= 0.59
5 Mean gestational age 31.12 ± 6.71 29.93 ± 5.54 p= 0.08
6 FBS (mmol/L) 3.29 ± 2.38 3.55 ± 8.29 p= 0.61
7 PPBG (mmol/L) 3.91 ± 3.31 4.04 ± 3.97 p= 0.14
8 GCT (mmol/L) 1.39 ± 3.45 1.81 ± 3.84 p= 0.39
9 TG (mmol/L) 1.81 ± 1.04 1.74 ± 0.96 p= 0.46
10 TC (mmol/L) 5.41 ± 1.26 5.12 ± 1.00 p= 0.03
11 HDL-C (mmol/L) 0.62 ± 0.25 0.64 ± 0.24 p= 0.69
12 LDL-C (mmol/L) 3.95 ± 1.06 3.60 ± 0.87 p= 0.07
13 Family history of T2DM (n%) 20 (41.6%) 100 (65.8%) NA
14 Family history of GDM (n%) 11 (22.9%) 35 (23%) NA
15 Rx (Diet/Insulin) 46 (95.8%)/2 (4.2%) 134 (88.2%)/18 (11.8%) NA
16 OGTT (Fasting hour) 4.26 ± 2.68 3.70 ± 2.54 p= 0.61
17 OGTT (1st hour) 8.41 ± 4.89 7.66 ± 5.07 p= 0.79
18 OGTT (2nd hour) 7.28 ± 4.20 6.47 ± 4.37 p= 0.77
19 OGTT (3rd hour) 3.76 ± 2.92 3.26 ± 3.14 p= 0.57
NA= not applicable/not analyzed.
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Table 5 Association of 12Glu9 polymorphism of ADRA2B gene in relation to different diseases and population of ethnicity.
S. No Disease Population p Value Association References
1 Type 2 diabetes mellitus + Hypertension Malaysian p= 0.51 No Vasudevan et al. (2008)
2 Acute coronary events Finland/Sweden p= 0.03 Yes Heinonen et al. (1999, 2002)
3 Acute coronary events Finland p= 0.02 Yes Snapir et al. (2001, 2003)
4 T2DM+Neuropathy Greece p= 0.0008 Yes Papanas et al. (2007)
5 Insulin Secretion + T2DM Finland p= 0.04 Yes Siitonen et al. (2004)
6 T2DM Greece p= 0.40 No Papazoglou et al. (2006)
7 Sudden cardiac death (SCD) Finland p< 0.05 Yes Laukkanen et al. (2009)
8 Spontaneous recurrent abortions Greece p= 0.78 No Galazios et al. (2011)
9 Migraine Chinese p= 0.35 No Ni et al. (2010)
10 Glucose 6 phosphate dehydrogenase Saudi p= 0.68 No Alharbi et al. (2013)
11 Suicide Japanese p= 0.04 Yes Fukutake et al. (2008)
12 Artery compliance Chinese p= 0.73 No Zhang et al. (2005)
13 Cardiac conduction Russian p< 0.05 Yes Chernova et al. (2013)
14 Hypertension Scandinavian p= 0.04 Yes Von Wowern et al.(2004)
15 Myocardial ischemia + T2DM Chinese p< 0.05 Yes Chen et al. (2010)
16 Obesity Greece p> 0.05 No Sykiotis et al. (2003)
17 Myocardial infarction + SCD Finland p= 0.01 Yes Snapir et al. (2001, 2003)
18 Gestational diabetes mellitus Saudi p= 0.0002 Yes Present study
Table 6 Genotype distribution of 12Glu9 polymorphism of ADRA2B gene in controls vs different forms of diabetes in relation to
ethnicity.

















II 152 (76) 265 (88.4) 72 (55.4) 46 (76.70) 6 (8.57) 7 (10.77) 18 (24)
ID 35 (17.5) 28 (9.3) 46 (35.4) 14 (23.3) 34 (48.57) 28 (43.08) 35 (46.67)
DD 13 (6.5) 7 (2.3) 12 (9.2) 0 (0) 30 (42.86) 30 (46.15) 22 (29.33)
ID + DD 48 (24) 35 (11.6) 60 (44.6) 14 (23.3) 64 (91.43) 58 (89.23) 57 (76)
I 339 (84.8) 558 (93) 190 (73.07) 106 (88.3) 46 (32.86) 42 (32.31) 71 (47.33)
DD 61 (15.2) 42 (7) 70 (26.93) 14 (11.7) 94 (67.14) 88 (67.69) 79 (52.67)
OR 2.3 (1.5,3.6) 2.789 (1.4–5.1) 0.545 (0.3–0.8)
p-Value p= 0.0002 p= 0.0008 p= 0.012
132 M.M. Al-Hakeem et al.variants in different diseases. The 12Glu9 polymorphism was
studied in relation to multiple diseases, and the reports are
summarized in Table 5.
In this case–control study, we ﬁnd signiﬁcant differences in
the distribution of the 12Glu9 or I/D polymorphism among
GDM and non-GDM subjects. A signiﬁcant association was
found between the genotypes and the GDM status, obesity,
or dyslipidemia, indicating that these polymorphisms may be
important risk determinants of cardio or metabolic disease
in Saudi women. Furthermore, our data suggest that I/D
polymorphism contribute to variation in expression of the
ADRA2B gene. In addition, no associations were noted
between genotype and anthropometric parameters, including
age and BMI, indicating that this polymorphism may not inde-
pendently contribute to obesity and advanced maternal age as
stated in the studied population. The results of this study also
indicated that the frequency of the heterozygous carriers and
homozygous variants of I/D polymorphism of ADRA2B was
signiﬁcantly higher in GDM women than in non-GDM
women.Papanas et al. (2007) studied T2DM with and without
nephropathy. The results of their study indicate that D allele
was signiﬁcantly higher (p= 0.001) in group A (26.9%) as
compared to group B (11.7%). Papanas et al. (2007) and co-
authors concluded that patients with neuropathy exhibit a sig-
niﬁcantly higher frequency of the D allele. Essential hyperten-
sion in a Malaysian population with and without T2DM was
studied earlier in three separate groups, controls, hypertension
with T2DM, and hypertension without T2DM. There was a
signiﬁcant difference between the genotype and clinical data
(p< 0.05), but there is no signiﬁcant difference between the
three genotypes and the clinical characteristics of the study
subjects (p> 0.05). The results obtained in the Malaysian
study indicated that the D allele in the ADRA2B gene was
associated with essential hypertension with and without
T2DM in Malaysian subjects (Vasudevan et al., 2008). In this
present study, the genotype distribution of the 12Glu9
polymorphism was strongly associated with GDM. This
consistency might be due to differences in genetic background
and sample size (Table 6). No clinical effects of this
Insertion and deletion polymorphism studies 133polymorphism were observed in this prospective study. This is
clearly a limitation of the study and indicates that the inﬂuence
on obesity risk of I/D polymorphism may be of major impor-
tance in GDM women. However, the subjects in our study had
a mean age greater than 30, which indicates the presence of
obesity in both GDM and non-GDM subjects.
In conclusion, the present study shows that 12glu9 poly-
morphism of the ADRA2B gene is associated with the risk of
GDM in a Saudi population. Further research is warranted
to conﬁrm the causality. The association of the DD genotype
and the D allele with GDM should be examined in multiple,
well-designed genetic epidemiological studies, and the physio-
logical effects should be identiﬁed.Conﬂict of interest
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